Differentially expressed androgen-regulated genes in androgen-sensitive tissues reveal potential biomarkers of early prostate cancer

PLoS One. 2013 Jun 28;8(6):e66278. doi: 10.1371/journal.pone.0066278. Print 2013.

Abstract

Background: Several data favor androgen receptor implication in prostate cancer initiation through the induction of several gene activation programs. The aim of the study is to identify potential biomarkers for early diagnosis of prostate cancer (PCa) among androgen-regulated genes (ARG) and to evaluate comparative expression of these genes in normal prostate and normal prostate-related androgen-sensitive tissues that do not (or rarely) give rise to cancer.

Methods: ARG were selected in non-neoplastic adult human prostatic epithelial RWPE-1 cells stably expressing an exogenous human androgen receptor, using RNA-microarrays and validation by qRT-PCR. Expression of 48 preselected genes was quantified in tissue samples (seminal vesicles, prostate transitional zones and prostate cancers, benign prostatic hypertrophy obtained from surgical specimens) using TaqMan® low-density arrays. The diagnostic performances of these potential biomarkers were compared to that of genes known to be associated with PCa (i.e. PCA3 and DLX1).

Results and discussion: By crossing expression studies in 26 matched PCa and normal prostate transitional zone samples, and 35 matched seminal vesicle and PCa samples, 14 genes were identified. Similarly, 9 genes were overexpressed in 15 benign prostatic hypertrophy samples, as compared to PCa samples. Overall, we selected 8 genes of interest to evaluate their diagnostic performances in comparison with that of PCA3 and DLX1. Among them, 3 genes: CRYAB, KCNMA1 and SDPR, were overexpressed in all 3 reference non-cancerous tissues. The areas under ROC curves of these genes reached those of PCA3 (0.91) and DLX1 (0.94).

Conclusions: We identified ARG with reduced expression in PCa and with significant diagnostic values for discriminating between cancerous and non-cancerous prostatic tissues, similar that of PCA3. Given their expression pattern, they could be considered as potentially protective against prostate cancer. Moreover, they could be complementary to known genes overexpressed in PCa and included along with them in multiplex diagnostic tools.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antigens, Neoplasm / genetics
  • Antigens, Neoplasm / metabolism
  • Biomarkers, Tumor / genetics
  • Biomarkers, Tumor / metabolism*
  • Carrier Proteins / genetics
  • Carrier Proteins / metabolism*
  • Cell Line, Tumor
  • Early Detection of Cancer
  • Gene Expression
  • Gene Expression Regulation, Neoplastic
  • Homeodomain Proteins / genetics
  • Homeodomain Proteins / metabolism
  • Humans
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / genetics
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits / metabolism*
  • Male
  • Metribolone / pharmacology
  • Organ Specificity
  • Phosphate-Binding Proteins
  • Prostate / metabolism
  • Prostatic Neoplasms / diagnosis*
  • Prostatic Neoplasms / genetics
  • Prostatic Neoplasms / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • ROC Curve
  • Real-Time Polymerase Chain Reaction
  • Seminal Vesicles / metabolism
  • Testosterone Congeners / pharmacology
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • alpha-Crystallin B Chain / genetics
  • alpha-Crystallin B Chain / metabolism*

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • CAVIN2 protein, human
  • CRYAB protein, human
  • Carrier Proteins
  • Distal-less homeobox proteins
  • Homeodomain Proteins
  • KCNMA1 protein, human
  • Large-Conductance Calcium-Activated Potassium Channel alpha Subunits
  • Phosphate-Binding Proteins
  • RNA, Messenger
  • Testosterone Congeners
  • Transcription Factors
  • alpha-Crystallin B Chain
  • prostate cancer antigen 3, human
  • Metribolone

Grants and funding

This work was supported by grants from the French League Against Cancer under the ”Equipe Labellisée” program, by the National Cancer Institute (INCA) and the National and Regional Cancer Programs. DA was a recipient of a PhD grant from the French Ministry of National Education, Research and Technology (MENRT Grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.